Macrocycle Delivery with Portal's Platform

Macrocycle

Who this is for

Lorem Ipsum

Start delivering now. Experimentally proven delivery workflows for live-cell screening and functional engineering with macrocycles.

Workflow	Example Cell Type	Cargo	Readout	What this Unlocks
Lorem	Lorem	Lorem	Lorem	Lorem

Highlighted Data and Applications

The percentage of live HeLa cells remained stable across escalating macrocycle concentrations (0.25 to 0.2 mg/ml) when treated with Portal’s delivery platform.

Sustained Viability in HeLa Cells Across Escalating Macrocycle Doses

Portal’s platform technology enables macrocycle delivery without compromising cell health. HeLa cell viability remained stable at ~80% across increasing macrocycle concentrations up to 0.2 mg/ml. This consistent viability across a wide dose range highlights exceptionally low cytotoxicity of Portal’s delivery method.

The percentage of FITC+ live cells showed a strong, dose-dependent increase, achieving nearly 100% intracellular delivery efficiency at 0.1 mg/ml and 0.2 mg/ml macrocycle concentrations.

Dose-Dependent Intracellular Delivery in HeLa Cells.

Intracellular delivery of macrocycles into HeLa cells was achieved with efficiency. Following delivery, the percentage of FITC-positive live cells showed a strong, clear, dose dependent increase. Untreated cells (0 mg/ml) exhibited 0% delivery, treated cells achieved approximately 50% delivery efficiency at lowest active dose of 0.025 mg/ml. This efficiency scaled up ~80% at 0.05 mg/ml, and achieved near-total intracellular delivery–approximtely 90% to 100% efficiency–at the peak macrocycle concentrations of 0.1 mg/ml and 0.2 mg/ml. These results demonstrate the platform’s ability to drive cargo uptake at scale while preserving overall cell integrity.

Visual Confirmation of Macrocycle Uptake in HEK293 Cells. Fluorescence microscopy of HEK293 cells revealed distinct intracellular accumulation of FITC-labeled macrocycles in the boosted group compared to the untreated group.

Delivery of Macrocycle to HEK293 cells

HEK293 cells treated with FITC-labeled macrocycles utilizing Portal’s delivery technology. Fluorescence microscopy provides visual evidence of successful macrocycle delivery, showing robust intracellular accumulation of FITC-labeled macrocycles in boosted HEK293 cells.

Intracellular Delivery in HEK293 Cells Quantified by Flow Cytometry. Flow cytometry data corroborates results shown by microscopy, demonstrating high percentages of FITC+ cells in the macrocycle-boosted group while maintaining high viability.

Macrocycle Delivery and Maintained Viability in HEK293 Cells

Flow cytometry demonstrates that the Portal delivery platform achieves exceptional efficiency while preserving overall HEK293 cell health. Quantitative analysis revealed ~80% successful uptake of FITC-labeled macrocycles by boosted cells. Crucially, this effective intracellular delivery was accomplished while maintaining strong overall viability at ~80%. These metrics demonstrate the platform's ability to balance highly efficient cargo delivery with the preservation of a robust live cell population.